{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glecaprevir-pibrentasvir",
    "query": {
      "intervention": "Glecaprevir-pibrentasvir"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 40,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glecaprevir-pibrentasvir&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T11:38:14.352Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04042740",
      "title": "Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Infection",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/Pibrentasvir (G/P)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2019-11-20",
      "completion_date": "2023-08-22",
      "has_results": true,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 11,
      "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04042740"
    },
    {
      "nct_id": "NCT04515797",
      "title": "QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Failure",
        "Hepatitis C",
        "Kidney Disease, Chronic"
      ],
      "interventions": [
        {
          "name": "Glecaprevir and Pibrentasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-05-01",
      "completion_date": "2023-08-31",
      "has_results": true,
      "last_update_posted_date": "2024-12-03",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04515797"
    },
    {
      "nct_id": "NCT03781726",
      "title": "Multi-center Study to Transplant Hepatitis-C Infected Kidneys",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Failure Chronic",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "glecaprevir/pibrentasvir treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raymond Chung",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2019-04-10",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 7,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03781726"
    },
    {
      "nct_id": "NCT03067129",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus (HCV)"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/Pibrentasvir Adult Formulation",
          "type": "DRUG"
        },
        {
          "name": "Glecaprevir + Pibrentasvir Pediatric Formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 129,
      "start_date": "2017-03-20",
      "completion_date": "2022-09-12",
      "has_results": true,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03067129"
    },
    {
      "nct_id": "NCT03801707",
      "title": "Utilization of Hepatitis C Positive Kidneys in Negative Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplant",
        "Hepatitis C",
        "HCV"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]",
          "type": "DRUG"
        },
        {
          "name": "Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2019-03-22",
      "completion_date": "2021-04-30",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03801707"
    },
    {
      "nct_id": "NCT07040319",
      "title": "Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/pibrentasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 45 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2026-06-25",
      "completion_date": "2028-03-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07040319"
    },
    {
      "nct_id": "NCT03164902",
      "title": "Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C, Chronic",
        "Nonadherence, Patient"
      ],
      "interventions": [
        {
          "name": "Digital Medicine",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Proteus Digital Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 253,
      "start_date": "2017-07-21",
      "completion_date": "2019-04-30",
      "has_results": false,
      "last_update_posted_date": "2018-12-13",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Colorado Springs, Colorado + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03164902"
    },
    {
      "nct_id": "NCT03092375",
      "title": "Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C",
        "HCV"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/Pibrentasvir (G/P) 300mg/120mg",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin 200Mg Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 177,
      "start_date": "2017-04-20",
      "completion_date": "2020-02-06",
      "has_results": true,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 31,
      "location_summary": "Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03092375"
    },
    {
      "nct_id": "NCT04575896",
      "title": "Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/pibrentasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-11-20",
      "completion_date": "2023-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-01-10",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04575896"
    },
    {
      "nct_id": "NCT02966795",
      "title": "A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus (HCV)"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/Pibrentasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2017-01-25",
      "completion_date": "2018-08-29",
      "has_results": true,
      "last_update_posted_date": "2021-07-30",
      "last_synced_at": "2026-09-25T11:38:14.352Z",
      "location_count": 6,
      "location_summary": "San Diego, California • San Francisco, California • West Hollywood, California + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02966795"
    }
  ]
}